1
|
Chirwa KA, Francisco KR, Dube PS, Park H, Legoabe LJ, Teixeira TR, Caffrey CR, Beteck RM. Tractable Quinolone Hydrazides Exhibiting Sub-Micromolar and Broad Spectrum Antitrypanosomal Activities. ChemMedChem 2024; 19:e202300667. [PMID: 38326914 PMCID: PMC11076157 DOI: 10.1002/cmdc.202300667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2023] [Revised: 01/12/2024] [Accepted: 02/07/2024] [Indexed: 02/09/2024]
Abstract
Nagana and Human African Trypanosomiasis (HAT), caused by (sub)species of Trypanosoma, are diseases that impede human and animal health, and economic growth in Africa. The few drugs available have drawbacks including suboptimal efficacy, adverse effects, drug resistance, and difficult routes of administration. New drugs are needed. A series of 20 novel quinolone compounds with affordable synthetic routes was made and evaluated in vitro against Trypanosoma brucei and HEK293 cells. Of the 20 compounds, 12 had sub-micromolar potencies against the parasite (EC50 values=0.051-0.57 μM), and most were non-toxic to HEK293 cells (CC50 values>5 μM). Two of the most potent compounds presented sub-micromolar activities against other trypanosome (sub)species (T. cruzi and T. b. rhodesiense). Although aqueous solubility is poor, both compounds possess good logD values (2-3), and either robust or poor microsomal stability profiles. These varying attributes will be addressed in future reports.
Collapse
Affiliation(s)
- Kgothatso A Chirwa
- Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, 2520, South Africa
| | - Karol R Francisco
- Center for Discovery and Innovation in Parasitic Diseases, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
| | - Phelelisiwe S Dube
- Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, 2520, South Africa
| | - Hayoung Park
- Center for Discovery and Innovation in Parasitic Diseases, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
| | - Lesetja J Legoabe
- Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, 2520, South Africa
| | - Thaiz Rodrigues Teixeira
- Center for Discovery and Innovation in Parasitic Diseases, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
| | - Conor R Caffrey
- Center for Discovery and Innovation in Parasitic Diseases, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
| | - Richard M Beteck
- Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, 2520, South Africa
| |
Collapse
|
2
|
Dube PS, Legoabe LJ, Jordaan A, Sigauke L, Warner DF, Beteck RM. Quinolone analogues of benzothiazinone: Synthesis, antitubercular structure-activity relationship and ADME profiling. Eur J Med Chem 2023; 258:115539. [PMID: 37321107 DOI: 10.1016/j.ejmech.2023.115539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Revised: 05/31/2023] [Accepted: 05/31/2023] [Indexed: 06/17/2023]
Abstract
Mycobacterium tuberculosis (Mtb) has an impermeable cell wall which gives it an inherent ability to resist many antibiotics. DprE1, an essential enzyme in Mtb cell wall synthesis, has been validated as a target for several TB drug candidates. The most potent and developmentally advanced DprE1 inhibitor, PBTZ169, is still undergoing clinical development. With high attrition rate, there is need to populate the development pipeline. Using a scaffold hopping strategy, we imprinted the benzenoid ring of PBTZ169 onto a quinolone nucleus. Twenty-two compounds were synthesised and screened for activity against Mtb, with six compounds exhibiting sub micromolar activity of MIC90 <0.244 μM. Compound 25 further demonstrated sub-micromolar activity when evaluated against wild-type and fluoroquinolone-resistant Mtb strains. This compound maintained its sub-micromolar activity against a DprE1 P116S mutant strain but showed a significant reduction in activity when tested against the DprE1 C387S mutant.
Collapse
Affiliation(s)
- Phelelisiwe S Dube
- Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, 2520, South Africa
| | - Lesetja J Legoabe
- Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, 2520, South Africa.
| | - Audrey Jordaan
- Molecular Mycobacteriology Research Unit, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, 7925, South Africa
| | - Lester Sigauke
- Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, 2520, South Africa
| | - Digby F Warner
- Molecular Mycobacteriology Research Unit, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, 7925, South Africa
| | - Richard M Beteck
- Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, 2520, South Africa.
| |
Collapse
|
3
|
Dube P, Angula KT, Legoabe LJ, Jordaan A, Boitz Zarella JM, Warner DF, Doggett JS, Beteck RM. Quinolone-3-amidoalkanol: A New Class of Potent and Broad-Spectrum Antimicrobial Agent. ACS OMEGA 2023; 8:17086-17102. [PMID: 37214682 PMCID: PMC10193574 DOI: 10.1021/acsomega.3c01406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/02/2023] [Accepted: 04/18/2023] [Indexed: 05/24/2023]
Abstract
Herein, we describe 39 novel quinolone compounds bearing a hydrophilic amine chain and varied substituted benzyloxy units. These compounds demonstrate broad-spectrum activities against acid-fast bacterium, Gram-positive and -negative bacteria, fungi, and leishmania parasite. Compound 30 maintained antitubercular activity against moxifloxacin-, isoniazid-, and rifampicin-resistant Mycobacterium tuberculosis, while 37 exhibited low micromolar activities (<1 μg/mL) against World Health Organization (WHO) critical pathogens: Cryptococcus neoformans, Acinetobacter baumannii, and Pseudomonas aeruginosa. Compounds in this study are metabolically robust, demonstrating % remnant of >98% after 30 min in the presence of human, rat, and mouse liver microsomes. Several compounds thus reported here are promising leads for the treatment of diseases caused by infectious agents.
Collapse
Affiliation(s)
- Phelelisiwe
S. Dube
- Centre
of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom 2520, South Africa
| | - Klaudia T. Angula
- Centre
of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom 2520, South Africa
| | - Lesetja J. Legoabe
- Centre
of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom 2520, South Africa
| | - Audrey Jordaan
- SAMRC/NHLS/UCT
Molecular Mycobacteriology Research Unit, Department of Pathology, University of Cape Town Observatory, Cape Town 7925, South Africa
- Institute
of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch, Cape Town 7701, South Africa
| | - Jan M. Boitz Zarella
- Division
of Infectious Diseases, VA Portland Healthcare
System, Portland, Oregon 97239, United States
| | - Digby F. Warner
- SAMRC/NHLS/UCT
Molecular Mycobacteriology Research Unit, Department of Pathology, University of Cape Town Observatory, Cape Town 7925, South Africa
- Institute
of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch, Cape Town 7701, South Africa
- Wellcome
Centre for Infectious Diseases Research in Africa (CIDRI-Africa),
Faculty of Health Sciences, University of
Cape Town, Rondebosch, Cape Town 7701, South Africa
| | - J. Stone Doggett
- Division
of Infectious Diseases, VA Portland Healthcare
System, Portland, Oregon 97239, United States
| | - Richard M. Beteck
- Centre
of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom 2520, South Africa
| |
Collapse
|
4
|
Design, Synthesis and Pharmacological Evaluation of New Quinoline-Based Panx-1 Channel Blockers. Int J Mol Sci 2023; 24:ijms24032022. [PMID: 36768344 PMCID: PMC9916356 DOI: 10.3390/ijms24032022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Revised: 01/12/2023] [Accepted: 01/17/2023] [Indexed: 01/22/2023] Open
Abstract
Pannexins are an interesting new target in medicinal chemistry, as they are involved in many pathologies such as epilepsy, ischemic stroke, cancer and Parkinson's disease, as well as in neuropathic pain. They are a family of membrane channel proteins consisting of three members, Panx-1, Panx-2 and Panx-3, and are expressed in vertebrates. In the present study, as a continuation of our research in this field, we report the design, synthesis and pharmacological evaluation of new quinoline-based Panx-1 blockers. The most relevant compounds 6f and 6g show an IC50 = 3 and 1.5 µM, respectively, and are selective Panx-1 blockers. Finally, chemical stability, molecular modelling and X-ray crystallography studies have been performed providing useful information for the realization of the project.
Collapse
|
5
|
Sharma V, Das R, Kumar Mehta D, Gupta S, Venugopala KN, Mailavaram R, Nair AB, Shakya AK, Kishore Deb P. Recent insight into the biological activities and SAR of quinolone derivatives as multifunctional scaffold. Bioorg Med Chem 2022; 59:116674. [DOI: 10.1016/j.bmc.2022.116674] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Revised: 02/07/2022] [Accepted: 02/13/2022] [Indexed: 01/09/2023]
|